Press Releases

September 6, 2019

Chimeron Bio Announces Appointment of Dr. Afshin Safavi to Chairman of the Board

PHILADELPHIA–Chimeron Bio, a RNA therapy company based in Philadelphia pioneering a novel class of RNA therapeutics and vaccines, today announced the appointment of Dr. Afshin Safavi to its board. As the Chairman of the Board, Dr. Safavi will provide counsel on drug development strategies to propel the advancement of Chimeron Bio’s pipeline and the creation of transformative drugs for patients in need.

“We are excited to welcome Dr. Safavi to Chimeron Bio as we continue to advance our science and technology, build the pipeline and develop innovative RNA medicines for patients in need” said Jolly Mazumdar, Cofounder and CEO of Chimeron Bio. “Dr. Safavi’s track record in drug development gained at leading pharmaceutical and biotech institutions and knowledge and perspective in company growth will be instrumental as we grow as a biotech company”.

Dr. Afshin Safavi is a seasoned entrepreneur and investor in biotechnology, pharmaceutical, IT-technology, as well as Councilman for Cherry Hills Village, CO.  As founder and Chief Scientific Officer of BioAgilytix, he has grown the company to more than 300 employees with global footprint in USA and Europe.  He has extensive experience establishing and leading teams in pharmaceutical and manufacturing companies and is responsible for multiple drugs in the market today.  Prior to founding BioAgilytix Labs, he held leadership roles in other biotech and pharmaceutical companies such as AAIPharma, Talecris BioTherapeutics (Grifols), Nobex Corporation, GlaxoSmithKline and IGEN International. 

Dr. Afshin commented, “I am excited to join the talented team of Chimeron Bio, working alongside the executive team and other board members toward making Chimeron Bio a leading RNA therapy company.  Joining a company with the clear vision to put life-saving drugs in the market in combination with strong IP and experienced management, I have no doubt that this will be a successful and an exciting journey for everyone involved in Chimeron Bio.  Let’s work together to improve patients’ health and save lives.”   Dr. Safavi hold a B.S. in Biochemistry from UCLA, a Ph.D. in Biochemistry from University of Kentucky Medical School and has completed a postdoctoral assignment at the Emory University, Department of Pathology.

About Chimeron Bio

Chimeron Bio is a biotechnology company focused on the research of self-amplifying RNA (saRNA) towards development of novel RNA entities for various diseases. The company is using its proprietary ChaESAR particles to develop a pipeline in oncology, rare genetic disorders and infectious diseases.  For more information, visit www.chimeronbio.com

Media Inquiries

Interested in learning more about Chimeron Bio’s novel technology and the work we are doing to develop first-in-class self-amplifying RNA therapeutics?

Reach out to us at contact@chimeronbio.com today.

Follow Us